Alfasigma

Company snapshot

Alfasigma is a global pharmaceutical company founded over 75 years ago in Italy, where it is headquartered (in Bologna and Milan). The Group operates in over 100 markets spanning Europe, North and South America, Asia, and Africa. It has offices in many countries, including Italy, the US, Spain, Germany, Mexico, and China; production sites in Italy (Pomezia, RM; Alanno, PE; Sermoneta, LT; Trezzano

• 8 active pipeline program(s) linked via ClinicalTrials.gov.
• 25 US patent(s) indexed to this assignee profile.
• 8 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Alfasigma. Not investment advice.

• approval May 29, 2026

  GSK and Alfasigma Licensing Agreement, Servier's $2.5B Acquisition

Recent activity

Latest pipeline, patent, and corporate events for Alfasigma.

1. Jun 8, 2026 Clinical update

   GS-US-417-0304 — Phase 3

2. Jun 8, 2026 Clinical update

   GLPG-0634-CL-131 — Phase 1

3. Jun 8, 2026 Clinical update

   VE-CIP1002/2021 — Phase 1

4. Jun 8, 2026 Clinical update

   GS-US-418-3899 — Phase 3

5. Jun 8, 2026 Clinical update

   GLPG0634-CL-333 — Phase 3

View all clinical trial activity →

• What is Alfasigma?

  Alfasigma S.p.A is a pharma organization headquartered in BOLOGNA, IT. Primary therapeutic focus areas include Juvenile idiopathic arthritis, juvenile idiopathic arthritis, Axial Spondyloarthritis, Ulcerative colitis, Rheumatoid arthritis. NovaPharmaNews links 8 clinical program(

• Is Alfasigma publicly traded?

  Alfasigma appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

• What drugs does Alfasigma develop or market?

  We link 8 drug profile(s) where Alfasigma is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/alfasigma-s-p-a#company-drugs.

• What are the latest developments for Alfasigma?

  In the last 12 months our linked public records show 8 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Alfasigma focus on?

  Alfasigma focuses on Juvenile idiopathic arthritis, juvenile idiopathic arthritis, Axial Spondyloarthritis based on our analysis of their pipeline programs and drug development activities.